PURPOSE: A bone filler in which a sustained release therapeutic agent for osteoporosis is supported is provided to effectively treat fracture and enhance convenience of use by adding a carrier. CONSTITUTION: A bone filler contains a sustained release drug hydroxyl apatite microsphere and carrier. The sustained release drug is risedroante, etidronate, clodronate, neridronate, ibandronate, zoledronate, olpadronate or alendronate. The carrier is glycerol, hyaluronic acid, alginate, agar, heparin, methyl cellulose, hydroxyl prophyl cellulose, ethyl cellulose, hydroxyl ethylcellulose, cellulose ether, sodium carboxy methylcellulose, dextran sulfate, gelatin, collagen, saline, poly(N-isopropyl acrylamide)(PNIPAAm) hydrogel, pluronics, poly(propylene fumarate(PPF)), carboxy methyl cellulose(CMC), dextran, starch, antifungal agent, antiviral agent, antibacterial agent, vitamin, amino acid, peptide, fibronectin, or immune suppressant. The bone filler is process in a form of paste, sponge, gel and putty.인체탈회골(human demineralized bone matrix)에 골다공증치료제인 alendronate가 담지된 인산칼슘(hydroxy apatite) 마이크로스피어를 첨가하여 골다공증으로 인한 골절환자에게 사용하는 골충진재로써 캐리어를 첨가해 사용의 편의성을 높인 gel & putty 형태의 신형 골충진재이다.
